Evolution of methods to detect paraneoplastic antibodies

Area of Science:

• Neuroimmunology
• Oncology
• Diagnostic Assays

Background:

• Less than 1% of cancer patients develop adaptive immune responses producing antibodies against neuronal proteins.
• These antibodies are associated with paraneoplastic syndromes, necessitating their accurate detection for cancer identification.
• Various assay systems, including indirect immunofluorescence and live cell-based assays, have been developed over time.

Purpose of the Study:

• To discuss the evolution of antibody assays for detecting antibodies against nuclear, cytosolic, and membrane targets.
• To highlight the importance of antigen conformation in antibody detection, particularly for membrane targets.
• To present recent data supporting recommendations against the sole use of line blots and introduce promising new antigen-specific approaches.

Main Methods:

• Review of historical antibody detection systems (indirect immunofluorescence, live cell-based assays).
• Development of high-throughput, multi-antigen assays (line blots, ELISAs) for clinical use.
• Evaluation of new antigen-specific approaches for detecting antibodies to membrane targets.

Main Results:

• Traditional assays are effective for nuclear and cytosolic targets, but membrane targets pose challenges due to antigen conformation.
• Recent data indicate that line blots alone are insufficient for accurate antibody detection.
• A novel antigen-specific approach shows promise for detecting submembrane targets.

Conclusions:

• Assay evolution is critical for accurately detecting neuronal antibodies in paraneoplastic syndromes.
• Newer, antigen-specific methods are essential for reliable detection of antibodies targeting membrane proteins.
• These advancements aid in the timely search for specific cancers associated with these antibodies.